Renal Cell Carcinoma Perspective

 
 

  • AUA 2022 Read clinically focused news coverage of key developments from AUA 2022
  • Renal Cell Carcinoma Highlights From ASCO-GU 2022   The role of immunotherapy at various disease stages and the predictive power of preoperative sarcopenia are among the highlights in renal cell carcinoma from ASCO-GU 2022 reviewed by Dr Brian Shuch.
  • GUCS 2022 Read clinically focused news coverage of key developments from GUCS 2022
  • Renal Cell Carcinoma: Achieving Complete Response   "One of the most gratifying patient experiences that I've had," says Sandy Srinivas in recounting a patient with RCC who achieved a complete response.
  • The Evolution of Treatment Options in Renal Cell Carcinoma   Eric Jonasch, MD, follows the trajectory of RCC treatments that have been developed during his career.
  • Renal Cell Carcinoma: A Flourishing Landscape   "I've been taking care of patients with kidney cancer now for more than 25 years, and a lot has changed in this field," says Sandy Srinivas in recalling an experience with an RCC patient in 2011.
  • Advice on Managing Advanced Renal Cell Carcinoma: Think Prospectively and Never Give Up   "Never give up," says Eric Jonasch, MD, in recalling a patient with metastatic ccRCC who started responding to therapy after progressing through three lines of treatment.
  • Find Individuals That Inspire You   Eric Jonasch, MD, reflects on the impact that his mentor had on his philosophy and approach to the treatment of patients with renal cell carcinoma.
  • Unmet Needs in the Era of Precision Medicine for RCC   Sandy Srinivas, MD, examines the current unmet needs for patients with renal cell carcinoma and discusses how the KEYNOTE-564 trial can help identify the right patient for the right therapy.
  • RCC e-Tumor Boards: Case 1: Metastatic Clear Cell Renal Cell Carcinoma   The e-Tumor Boards, a video series collaboration with Memorial Sloan Kettering Cancer Center, gives physicians an inside look into a virtual, multidisciplinary renal cell carcinoma tumor board case discussion.
  • Renal Cell Carcinoma Highlights From ESMO 2021   Dr Brian Rini, of Vanderbilt University, discusses key RCC abstracts from ESMO 2021, including data on efficacy and quality-of-life endpoints from the STAR, PRISM, and KEYNOTE-564 trials.
  • AUA 2021 Read clinically focused news coverage of key developments from AUA 2021
  • EAU 2021 Read clinically focused news coverage of key developments from EAU 2021
  • Highlights in Renal Cell Carcinoma From ASCO 2021   From ASCO 2021, Dr Eric Jonasch reports on advances for patients with renal cell carcinoma, including results from the KEYNOTE-564 study and the quality-of-life update from the CLEAR trial.
  • Highlights in RCC From ASCO 2021 GU Cancers Symposium   From ASCO GU 2021, Dr Daniel George reports on advances for patients with renal cell carcinoma, including results from the CLEAR study, CheckMate 9ER, and SWOG 1500.
  • GUCS 2021 Read clinically focused news coverage of key developments from GUCS 2021
  • Metastatic RCC Highlights From IKCS 2020   Dr Brian Rini reports key results in metastatic RCC from IKCS 2020, including early evidence of benefit from lenvatinib-everolimus in non-clear cell RCC, and an alternative ipilimumab-nivolumab dose.
  • Renal Cell Carcinoma Highlights From ESMO 2020   Dr Robert Motzer reviews key studies on renal cell carcinoma presented at the 2020 ESMO Virtual Congress, including phase 3 trial results showing benefit from combination therapies in advanced RCC.
  • ASCO Plenary Highlights Importance of Publicly Funded Research The question posited by the E2108 study, which is being presented at this year's ASCO annual meeting, may not have a financial incentive, but it is vital for clinical practice.
  • AUA 2020 Read clinically focused news coverage of key developments from AUA 2020